Ignite Creation Date:
2025-12-24 @ 5:56 PM
Ignite Modification Date:
2025-12-30 @ 8:44 AM
Study NCT ID:
NCT05973968
Status:
UNKNOWN
Last Update Posted:
2023-08-04
First Post:
2023-07-16
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Surufatinib in G3 Neuroendocrine Tumors
Sponsor:
Qilu Hospital of Shandong University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-08
Start Date Type:
ESTIMATED
Primary Completion Date:
2024-06
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-06
Completion Date Type:
ESTIMATED
First Submit Date:
2023-07-16
First Submit QC Date:
None
Study First Post Date:
2023-08-03
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-08-02
Last Update Post Date:
2023-08-04
Last Update Post Date Type:
ACTUAL